Kestra Private Wealth Services LLC Acquires 527 Shares of Moderna, Inc. (NASDAQ:MRNA)

Kestra Private Wealth Services LLC boosted its position in Moderna, Inc. (NASDAQ:MRNAFree Report) by 11.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 5,267 shares of the company’s stock after purchasing an additional 527 shares during the period. Kestra Private Wealth Services LLC’s holdings in Moderna were worth $544,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of MRNA. ICA Group Wealth Management LLC acquired a new stake in Moderna during the fourth quarter worth approximately $27,000. First Pacific Financial acquired a new stake in Moderna during the third quarter worth approximately $27,000. Stonebridge Capital Advisors LLC lifted its position in Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after acquiring an additional 125 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in Moderna by 173.5% during the first quarter. Parkside Financial Bank & Trust now owns 309 shares of the company’s stock worth $53,000 after acquiring an additional 196 shares during the last quarter. Finally, Ancora Advisors LLC raised its position in shares of Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after buying an additional 96 shares in the last quarter. 64.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the completion of the sale, the president now directly owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the completion of the sale, the president now directly owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 772 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $109.75, for a total transaction of $84,727.00. Following the transaction, the chief financial officer now directly owns 3,632 shares of the company’s stock, valued at $398,612. The disclosure for this sale can be found here. Insiders have sold 106,899 shares of company stock worth $10,732,838 in the last quarter. Insiders own 15.70% of the company’s stock.

Moderna Trading Down 0.7 %

MRNA opened at $99.30 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.35 and a current ratio of 2.46. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $177.37. The company’s 50-day moving average is $95.74 and its 200 day moving average is $96.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MRNA shares. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and dropped their price target for the company from $89.00 to $69.00 in a research report on Friday, November 3rd. The Goldman Sachs Group dropped their price target on shares of Moderna from $269.00 to $231.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Moderna from a “hold” rating to a “sell” rating and dropped their price target for the company from $125.00 to $60.00 in a research report on Thursday, November 2nd. TheStreet downgraded shares of Moderna from a “c” rating to a “d” rating in a research report on Thursday, November 2nd. Finally, Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $123.96.

View Our Latest Report on MRNA

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.